Fluence

Dr. Elizabeth Nielson is a co-founder of Fluence and a psychologist with a focus on developing psychedelic medicines as empirically supported treatments for PTSD, substance use problems, and mood disorders. Dr. Nielson is a therapist on FDA approved clinical trials of psilocybin-assisted treatment of alcohol use disorder, MDMA-assisted treatment PTSD, and psilocybin-assisted treatment of treatment resistant depression. Through Fluence, she provides continuing education and training programs for therapists who wish to engage in integration of psychedelic experiences in clinical settings. Her program of research includes qualitative and mixed-methods projects designed to further understand the phenomenology and mechanisms of change in psychedelic-assisted therapy, including the experiences of trial participants and of the therapists themselves. Having completed an NIH postdoctoral fellowship at NYU, she has published and presented on topics of psychedelic therapist training, therapists’ personal experience with psychedelics, and including psychedelic integration in group and individual psychotherapy.

Dr. Ingmar Gorman is a psychologist who specializes in helping people who use psychedelics and other psychoactive compounds. He received his clinical training at the New School for Social Research, Mount Sinai Beth Israel Hospital, Columbia University, and Bellevue Hospital. He completed his NIH postdoctoral fellowship at New York University in 2017. Dr. Gorman was formerly the Director of the Psychedelic Education and Continuing Care Program at the Center for Optimal Living and is now the co-founder of Fluence, a psychedelic education company training mental health providers in psychedelic treatments. Along with Dr. Paleos, he is currently site co-principal investigator and therapist on a Phase 3 clinical trial of MDMA-assisted Psychotherapy for Post-Traumatic Stress Disorder.

Casey Paleos, MD is a psychiatrist and researcher with over a decade of experience in the use of psychedelic medicines for the treatment of mental illness, dating back to his work, while still in residency training, as a study therapist in the landmark Psilocybin Cancer Anxiety Study at NYU, where Dr. Guss was one of his mentors. Since then, Dr. Paleos was Co-Principal Investigator in the NYU-Bellevue Ketamine for Depression Study and has been treating patients in his private practice with both ketamine infusion therapy and ketamine-assisted psychotherapy since 2016. Presently, he is a study therapist and Principal Investigator, alongside Dr. Gorman, in the MAPS-sponsored MDMA-Assisted Psychotherapy for PTSD Phase 3 Clinical Trial, serves as Scientific Director at Mindbloom, Inc., and is a co-founder of Nautilus Sanctuary, a non-profit psychedelic research and clinical institution based in New York City.